Trial Profile
An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2020
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Intec Pharma
- 03 Feb 2012 Status changed from recruiting to completed, as reported in an Intec Pharma media release.
- 04 Feb 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 03 Feb 2010 Primary endpoint 'Drug-concentration' has been met.